Suppr超能文献

抗菌肽抗性进化改变了最低抑菌浓度(MIC)之外的药效学。

Resistance Evolution Against Antimicrobial Peptides in Alters Pharmacodynamics Beyond the MIC.

作者信息

El Shazely Baydaa, Yu Guozhi, Johnston Paul R, Rolff Jens

机构信息

Evolutionary Biology, Institute for Biology, Free University of Berlin, Berlin, Germany.

Zoology Department, Faculty of Science, Alexandria University, Alexandria, Egypt.

出版信息

Front Microbiol. 2020 Feb 14;11:103. doi: 10.3389/fmicb.2020.00103. eCollection 2020.

Abstract

Antimicrobial peptides (AMPs) have been proposed as a promising class of new antimicrobials partly because they are less susceptible to bacterial resistance evolution. This is possibly caused by their mode of action but also by their pharmacodynamic characteristics, which differ significantly from conventional antibiotics. Although pharmacodynamics of antibiotic resistant strains have been studied, such data are lacking for AMP resistant strains. Here, we investigated if the pharmacodynamics of the Gram-positive human pathogen evolve under antimicrobial peptide selection. Interestingly, the Hill coefficient (kappa κ) evolves together with the minimum inhibition concentration (MIC). Except for one genotype, strains harboring mutations in F and , all mutants had higher kappa than the non-selected sensitive controls. Higher κ results in steeper pharmacodynamic curve and, importantly, in a narrower mutant selection window. selected for resistance to melittin displayed cross resistant against pexiganan and had as steep pharmacodynamic curves (high κ) as pexiganan-selected lines. By contrast, the pexiganan-sensitive tenecin-selected lines displayed lower κ. Taken together, our data demonstrate that pharmacodynamic parameters are not fixed traits of particular drug/strain interactions but actually evolve under drug treatment. The contribution of factors such as κ and the maximum and minimum growth rates on the dynamics and probability of resistance evolution are open questions that require urgent attention.

摘要

抗菌肽(AMPs)已被认为是一类很有前景的新型抗菌剂,部分原因是它们较不易受到细菌耐药性进化的影响。这可能是由它们的作用方式引起的,但也与其药效学特性有关,这些特性与传统抗生素有显著差异。尽管已经对抗生素耐药菌株的药效学进行了研究,但对于抗菌肽耐药菌株却缺乏此类数据。在此,我们研究了革兰氏阳性人类病原体的药效学在抗菌肽选择下是否会发生演变。有趣的是,希尔系数(kappa κ)与最低抑菌浓度(MIC)一起发生了演变。除了一种基因型外,在F和 中携带突变的菌株,所有突变体的kappa都高于未选择的敏感对照。较高的κ会导致药效学曲线更陡峭,重要的是,会使突变体选择窗口变窄。选择对蜂毒肽耐药的菌株对聚甘肽显示出交叉耐药性,并且其药效学曲线(高κ)与聚甘肽选择的品系一样陡峭。相比之下,对聚甘肽敏感的tenecin选择的品系显示出较低的κ。综上所述,我们的数据表明,药效学参数不是特定药物/菌株相互作用的固定特征,而是实际上会在药物治疗下发生演变。诸如κ以及最大和最小生长速率等因素对耐药性进化的动态和概率的贡献是需要迫切关注的开放性问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ad/7033599/bce0aa2a4534/fmicb-11-00103-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验